Atour Lifestyle (ATAT) stock slides about 4% in U.S. trade as rate bets shift, CPI looms

Atour Lifestyle (ATAT) stock slides about 4% in U.S. trade as rate bets shift, CPI looms

NEW YORK, Jan 9, 2026, 13:24 EST — Regular session

  • Atour Lifestyle shares fell about 4% in early afternoon trading after swinging sharply at the open.
  • The pullback comes as investors digest soft U.S. payrolls data and the outlook for Fed policy and tariffs.
  • Next focus: U.S. CPI on Jan. 13 and the Fed’s late-January meeting.

Atour Lifestyle Holdings’ U.S.-listed shares slid 4.2% to $40.20 in early afternoon trading on Friday, after moving between $39.85 and $42.02. Trading volume was about 894,000 shares.

The decline comes as Wall Street digests fresh U.S. data that nudged rate-cut odds lower, while investors also track the legal fight over President Donald Trump’s tariffs. “Payrolls were a little bit light relative to consensus, but still fairly strong numbers,” Tim Ghriskey, a senior portfolio strategist at Ingalls & Snyder, said. (Reuters)

The Labor Department reported nonfarm payrolls rose by 50,000 jobs in December, below expectations for 60,000, while the unemployment rate eased to 4.4%. “It’s an employment report that’s not too hot, not too cold,” Peter Cardillo, chief market economist at Spartan Capital Securities, said. (Reuters)

The selloff in Atour outpaced declines in some China travel and lodging names. Rival H World Group was down about 2.0%, while online travel group Trip.com fell about 0.9%; Marriott shares rose about 1.4%.

Atour operates a hotel chain in China and has built a retail business that sells products linked to guests’ stays, including sleep-focused goods. (Reuters)

Investors now turn to inflation data for another read on the path for U.S. interest rates. The U.S. Consumer Price Index report for December 2025 is due on Tuesday, Jan. 13, at 8:30 a.m. ET, according to the Bureau of Labor Statistics schedule. (Bureau of Labor Statistics)

But the setup cuts both ways. Any fresh flare-up in tariff headlines or another swing in rate expectations can hit risk appetite quickly, and China-linked ADRs can gap on policy news that has little to do with hotel bookings.

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Accenture stock price today: ACN slips as jobs data resets rate bets, new retail AI push in focus
Previous Story

Accenture stock price today: ACN slips as jobs data resets rate bets, new retail AI push in focus

WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus
Next Story

WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus

Go toTop